Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian B McDermott

Showing results (121-130 of 179) with videos related to

Pageof 18
Sort By:
Cell Reports|August 7, 2020
Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell SignatureCheng Cheng, Hongying Duan, Kai Xu, et al.
Science Translational Medicine|January 20, 2017
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodiesConstantinos Petrovas, Sara Ferrando-Martinez, Michael Y Gerner, et al.
Journal of Virology|May 30, 2006
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Nancy A Wilson, Jason Reed, Gnankang S Napoe, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Journal of Virology|November 25, 2005
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing GagDanilo R Casimiro, Fubao Wang, William A Schleif, et al.
The Lancet. Infectious Diseases|August 9, 2025
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance studyHai Nguyen-Tran, Sang Woo Park, Matthew R Vogt, et al.
Science Translational Medicine|May 6, 2026
VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declinesAlka Khaitan, Jane C Lindsey, Edmund V Capparelli, et al.
Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Pageof 18

Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
Cell Reports|August 7, 2020
Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell SignatureCheng Cheng, Hongying Duan, Kai Xu, et al.
Science Translational Medicine|January 20, 2017
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodiesConstantinos Petrovas, Sara Ferrando-Martinez, Michael Y Gerner, et al.
Journal of Virology|May 30, 2006
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Nancy A Wilson, Jason Reed, Gnankang S Napoe, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Journal of Virology|November 25, 2005
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing GagDanilo R Casimiro, Fubao Wang, William A Schleif, et al.
The Lancet. Infectious Diseases|August 9, 2025
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance studyHai Nguyen-Tran, Sang Woo Park, Matthew R Vogt, et al.
Science Translational Medicine|May 6, 2026
VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declinesAlka Khaitan, Jane C Lindsey, Edmund V Capparelli, et al.
Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Pageof 18